A Phase 2 Study of Neo-adjuvant Metformin and Temozolomide followed by Hypofractionated Accelerated RadioTherapy (HART) with Concomitant and Adjuvant Metformin and Temozolomide (TMZ) in Patients with Glioblastoma
George Shenouda, Bassam Abdulkarim(University of Alberta), Jeffery A. Hall(McGill University), Luís Souhami(McGill University Health Centre), Tânia Carvalho(University of Lisbon), Valérie Panet-Raymond(McGill University Health Centre), Scott Owen(McGill University Health Centre), Roberto J. Diaz(Montreal Neurological Institute and Hospital), Marie Christine Guiot(Montreal Neurological Institute and Hospital), Kevin Petrecca(McGill University Health Centre)
International Journal of Radiation Oncology*Biology*Physics
October 23, 2020
Cited by 7
Related Papers
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
|The Lancet|2004|2.4k
Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix
|Journal of Clinical Oncology|2000|2.3k
Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05
|International Journal of Radiation Oncology*Biology*Physics|2000|1.6k
Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
|Journal of Clinical Oncology|2012|1.2k